Investor Relations
FR | EN
|
||
|
|
||
|
||
|
|
||
|
||
|
|
||
|
||
|
|
||
|
||
|
|
||
|
||
|
|
||
|
||
|
|
||
|
||
|
|
||
|
||
|
|
||
|
The genOway Share
Share Price
Stock Market : Euronext Growth
Ticker : ALGEN
Code ISIN : FR004053510
Number of outstanding shares : 9 046 590
First day of trading : May 7, 2007 Share –liquidity contracts
Shareholders
Nextstage AM: 16,8%
Alexandre Fraichard: 9,8%
Employees and Board Members: 8,5%
Group of Investors Lyon*: 6,8%
Eximium: 5,8%
genOway Autodetention: 2,8%
Pasteur Institute: 0,8%
Free Float: 48,8%
* Shareholders acting together
Financial Calendar
Turnover 2023: 16 January 2024
Investor relations
Please contact us at: finances@genoway.com
Analysts
Euroland Corporate supports genOway by monitoring and disseminating financial analysis to institutional and individual investors.
Study published on 22 November 2023
"Accelerating the introduction of innovative therapies":
- Recommendation to purchase genOway shares
- Price target set at €5.80, i.e. a potential of + 41%
This financial analysis is available on the Euroland Corporate (www.elcorp.com/nos-analysesfinancieres) website and by clicking here.
Financial Press Releases
22 November 2023: Initiation de la couverture du titre genOway par Euroland Corporate (Only available in French)
17 October 2023: genOway crée une coentreprise à Shanghai avec pour objectif de devenir le partenaire de référence de la recherche préclinique en Chine (Only available in French)
21 September 2023: genOway: Financial results for the first half of 2023 (Only available in French)
31 August 2023: New technological success for genOway's humanized ICP (Immune Checkpoint) models, effectively used by Curadev Pharma in preclinical trials of its drug candidate CRD3874 for the treatment of advanced/metastatic solid cancers (Only available in French)
18 July 2023: 2023 Half-year revenues (Only available in French)
07 June 2023: New commercial success of genOway's immuno-oncology catalog models: first patient recruited by the laboratory Sensei Biotherapeutics for its anti-VISTA (Only available in French)
06 April 2023: genOway: Financial results for 2022 (Only available in French)
16 January 2023: genOway: Turnover 2022 (Only available in French)
19 September 2022: genOway: Financial results for the first half of 2022 (Only available in French)
08 septembre 2022 : Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance
18 July 2022: 2022 Half-year revenues (Only available in French)
23 May 2022: genOway: Proposal of a new administrator
28 March 2022: genOway: Financial results for 2021 (Only available in French)
31 January 2022: genOway: Turnover 2021 (Only available in French)
16 November 2021: genOway accelerates its cell model development and signs a major contract with an international pharmaceutical leader (Only available in French)
25 Octobre 2021 : genOway finalized the design of the 1st research model to accurately reproduce symptoms triggered by a respiratory virus such as Sars-Cov2 (Only available in French)
27 September 2021: genOway: Financial results for the first half of 2021 (Only available in French)
19 July 2021: 2021 Half-year revenues
27 May 2021: genOway raises €5.6 million at a price of €4 the share to finance the development of new R&D projects and to accelerate the commercial deployment of its catalog offer in immuno-oncology (Only available in French)
6 May 2021: Proposed capital increase of approximately €5 million per private placement at a price of €4 per share (Only available in French)
30 March 2021: genOway: Financial results for 2020 (Only available in French)
26 January 2021: Delivery of a 1st European patent for SMASh technology for which genOway has acquired an exclusive and worldwide license (Only available in French)
19 January 2021: genOway: Turnover 2020 (Only available in French)
05 January 2021: genOway obtains €2,3M from the European Union and the Auvergne-Rhône-Alpes Region to develop humanized immune checkpoint models
09 October 2020: Nobel Prize in Chemistry for the discovery of the CRISPR/Cas9 system
17 September 2020: genOway: Financial results for the first half of 2020 (Only available in French)
16 July 2020: genOway: 2020 Half-year revenues (Only available in French)
29 June 2020 : genOway invests in a new laboratory to produce its next-generation immunodeficient BRGSF-HIS models (Only available in French)
26 March 2020: genOway: Financial results for 2019 (Only available in French)
24 February 2020: Deliver of a 1st American patent for SMASh technology for which genOway has acquired an exclusive and worldwide license (Only available in French)
28 January 2020: genOway accomplishes a fundraising of 6,2 M€ to accompany its new strategy (Only available in French)
15 January 2020: genOway: Turnover 2019 (Only available in French)
07 January 2020: genOway and Merck strengthen CRISPR/Cas9 strategic alliance by extending their partnership to all animal cell models
04 November 2019: The Institut Pasteur and Cellectis extend exclusive license rights by granting genOway the authority to take action against infringement
31 October 2019: genOway roadshow investisseurs (Only available in French)
25 September 2019: Forum LPB Valeurs Régionales (Only available in French)
23 September 2019: genOway: Financial results for the first half of 2019 (Only available in French)
27 March 2019: Evolution of the genOway governance (Only available in French)
27 May 2019: genOway licenses the Flex technology rights to HHMI for the distribution of its AAV FLEX
28 March 2019: genOway: Financial results for 2018 (Only available in French)
21 January 2019: genOway: Turnover 2018 (Only available in French)
10 December 2018: Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
10 September 2018: genOway: Financial results for the first half of 2018 (Only available in French)
4 September 2018: genOway acquires Axenis, 1st step of it's new strategical plan 2018-2022 (Only available in French)
4 September 2018: Legal modalities of the acquisition of the society Axenis by genOway (Only available in French)
16 July 2018: New strategic plan 2018-2022 (Only available in French)
16 July 2018: genOway: 2018 Half-year revenues (Only available in French)
20 June 2018: genOway allows Addgene to distribute its FLEX technology
3 April 2018: genOway: Financial results for 2017 (Only available in French)
23 January 2018: genOway: 2017 Revenues (Only available in French)
14 September 2017: genOway: Financial results for the first half of 2017 (Only available in French)
11 July 2017: genOway: 2017 Half-year revenues (Only available in French)
30 March 2017: genOway: Financial results for 2016 (Only available in French)
16 January 2017: genOway: 2016 Revenues (Only available in French)
19 December 2016: Two more contracts with TOP 20 pharmaceutical leaders signed; First objective of strategical plan reached (Only available in French)
12 September 2016: genOway: Financial results for the first half of 2016 (Only available in French)
12 July 2016: genOway: 2016 Half-year revenues (Only available in French)
13 June 2016 : genOway maintains its momentum with 2 new 3-year contracts signed with TOP 10 pharmaceutical leaders (Only available in French)
29 February 2016: genOway: Financial results for 2015 (Only available in French)
29 February 2016: genOway adds a new Worldwide Top 5 pharmaceutical leader to it’s clients portfolio; with a signed 5-years contract (Only available in French)
18 January 2016: Second contract with one of the Worldwide Top 5 pharmaceutical companies, aiming at an annual turnover of 1 Million USD (Only available in French)
08 December 2015: A new contract with a major biopharmaceutical company with a turnover of estimated one million euro per year during 3 years (Only available in French)
05 October 2015: Benjamin Bruneau est nommé Directeur Administratif et Financier de genOway (Only available in French)
01 October 2015: genOway: Financial results for the first half of 2015 (Only available in French)
16 Mars 2015: genOway: Financial results for 2014 (Only available in French)
15 Mars 2015: In 3 years from now to the worldwide leader for the development of genetically modified research models. (Only available in French)
17 October 2014: genOway: Financial results for the first half of 2014 (Only available in French)
06 October 2014: Christian Grenier is nominated Chairman of the Board of genOway (Only available in French)
2 July 2014: genOway offers industry scientists immediate access to EUCOMM conditional KO mouse models
2 June 2014: New Accelerated Knockin / Humanization™ platform
28 May 2014: genOway signs new contracts in Israel and Gulf Arab States (Only available in French)
15 May 2014: genOway acquires exclusive sublicensing rights for the FLEx technology
03 Avril 2014: genOway: eligible for the new PEA-PME (Only available in French)
31 Mars 2014 : genOway: Financial results for 2013 (Only available in French)
04 February 2014: Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
30 Septembre 2013: genOway: Financial results for the first half of 2013 (Only available in French)
25 Mars 2013: genOway: Financial results for 2012 (Only available in French)
28 septembre 2012: genOway: Financial results for the first half of 2012 (Only available in French)
26 avril 2012: genOway signe un contrat cadre avec l'une des meilleures universités américaines (Only available in French)
30 mars 2012: genOway : Financial results for 2011 (Only available in French)
29 mars 2012: De la start up de l'ENS de Lyon à l'entreprise internationale. (Only available in french)
20 March 2012: StemCells, Inc. grants genOway exclusive license to gene insertion technology for genetically engineered mice
23 January 2012: genOway renewals framework agreement with major european University (Only available in French)
19 December 2011: genOway consolidates its position in the United States with the signing of two framework contracts with prestigious American Universities (Only available in French)
20 October 2011: Ralph L. Brinster will be awarded the next ISTT Prize sponsored by genOway at the TT2011 meeting in Miami
30 September 2011: genOway: Financial results for the first half of 2011 (Only available in French)
7 September 2011: genOway obtains its first patent for its "KO - KI" technology (Only available in French)
5 September 2011: Implementation of liquidity contract with PORTZAMPARC Brokerage Company (Only available in French)
12 July 2011: genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents
28 April 2011: genOway's customers fully satisfied with the company's offer and services (Dun & Bradstreet) (Only available in French)
31 March 2011: genOway annouces its financial results for 2010 (Only available in French)
20 January 2011: genOway commits against atherosclerosis and expands its range of products (Only available in French)
10 January 2011: Mr. Olivier Costa de Beauregard, Managing Director of the Dassault Group, has been nominated to genOway's Board of Directors
8 December 2010: genOway receives NYSE Euronext award from Deloitte Technology Fast 50 (Only available in French)
3 November 2010: genOway extends the exclusivity of its offer in pharmacology - toxicology (Only available in French)
1 October 2010: genOway: strong growth and increased profitability in the first half of 2010 (Only available in French)
20 September 2010: genOway announces General Service Agreements with Johann-Wolfgang-Goethe University Frankfurt (Only available in French)
6 September 2010: genOway: growth outlook reinforced by dynamic market (Only available in French)
7 July 2010: genOway: management strengthens its position in the capital of the Company (Only available in French)
14 June 2010: genOway improves its growth with major Japanese biopharmaceutical companies
8 June 2010: genOway : Edouard P. Croufer appointed to the Board of Directors
18 May 2010: genOway to present at the innovation week of the World Expo Shanghai 2010 (Only available in French)
3 May 2010: genOway renewals 2.5 million Euros biopharmaceutical agreement (Only available in French)
19 April 2010: genOway, a strategic partner for European programs Myores and AtheroRemo (Only available in French)
7 April 2010: genOway renewals framework agreement of several million Euros with one of the world's leading biopharmaceutical companies (Only available in French)
31 March 2010: genOway annouces its financial results for 2009 (Only available in French)
18 February 2010: genOway and Cellectis close their disagreement
21 December 2009: genOway chosen by Tufts University for major framework contract
15 December 2009: genOway : 2 years renewable framework agreement with the University of Pittsburgh, 6th U.S. research center (Only available in French)
7 December 2009: genOway announces important Framework agreement with BIDMC, Harvard Medical School's Teaching Hospital
13 November 2009: genOway will appeal the decision of the TGI of November 12, 2009 (Only available in French)
4 November 2009: genOway announces important framework agreement with UPenn (University of Pennsylvania) one of the top ten U.S universities (Only available in French)
29 October 2009: genOway launches its "Knock-in 2in1" technology based on its proprietary "StemCell HY" platform.
20 October 2009: genOway acquires exclusive license for Flex technology developed by Professor Pierre Chambon and Dr. Norbert Ghyselinck at the IGBMC
30 September 2009: genOway annouces its half year results for 2009 (Only available in French)
10 September 2009: genOway's expertise selected as part of the AD-Inov consortium
2 September 2009: genOway: strong growth of academic customer portfolio in the first semester of 2009
14 May 2009: genOway reports the expansion of its business with major biopharmaceutical companies in first quarter of 2009
6 April 2009: genOway annouces its financial results for 2008 (Only available in french)
11 February 2009: genOway introduces StemCellHY, a new production technology
13 January 2009: genOway announces a 2-year general agreement with the renowned IMM - University of Zurich
06 January 2009: genOway launches a legal action against Cellectis S.A. and claims several millions euros for compensation
29 September 2008: genOway annouces its half year results for 2008 (Only available in French)
7 April 2008: genOway announces its financial results for 2007. (Only available in French)
2 April 2008: genOway signs a major master services agreement with the Japanese pharmaceuticals leader Eisai Co. Ltd.
25 March 2008: genOway: master service agreement with Boehringer Ingelheim Pharmaceuticals Inc.
19 November 2007 : genOway launches standardized genetically modified mouse and rat research models
17 October 2007 : genOway signs a contract for up to 2 Million USD in intended services with a US-based leading biopharmaceutical firm
19 September 2007: genOway annouces its half year results for 2007 (Only available in French)
May 2007: genOway is successfully entering the stock market: Capital raised will accelerate the transgenic company's technological innovation and industrialization process (Only available in French)
23 March 2007: genOway annouces its financial results for 2006 (Only available in French)
Annual reports / Registration Documents
Annual reports and registration documents are only available in French.
Shareholder's Documentation
Annual Shareholder's meeting, June 29, 2023
Documentation only available in French.
Annual Shareholder's meeting, June 28, 2022
Documentation only available in French.
Annual Shareholder's meeting, May 26, 2021
Documentation only available in French.
Annual Shareholder's meeting, September 24, 2020
Documentation only available in French.
Annual Shareholder's meeting, December 16, 2019
Documentation only available in French.
Annual Shareholder's meeting, June 26, 2019
Documentation only available in French.
Annual Shareholder's meeting, November 05, 2018
Documentation only available in French.
Annual Shareholder's meeting, June 27, 2018
Documentation only available in French.
Annual Shareholder's meeting, June 28, 2017
Documentation only available in French.
Annual Shareholder's meeting, May 31, 2016
Documentation only available in French.
Annual Shareholder's meeting, June 23, 2015
Documentation only available in French.
Annual Shareholder's meeting, September 18, 2014
Documentation only available in French.
Annual Shareholder's meeting, June 30, 2014
Documentation only available in French.
Annual Shareholder's meeting, June 3, 2013
Documentation only available in French.
Annual Shareholder's meeting, June 4, 2012
Documentation only available in French.
Annual Shareholder's meeting, June 7, 2011
Documentation only available in French.
Annual Shareholder's meeting, January 6, 2011
Documentation only available in French.
Annual Shareholder's meeting, June 7, 2010
Documentation only available in French.
Annual Shareholder's meeting, June 8, 2009
Documentation only available in French.
Annual Shareholder's Meeting, June 26, 2008
Documentation only available in French.